Alexandra J Lansky, Bo Xu, Andreas Baumbach, Henning Kelbæk, Niels van Royen, Ming Zheng, Paul Knaapen, Ton Slagboom, Thomas W Johnson, Georgios J Vlachojannis, Karin E Arkenbout, Lene Holmvang, Luc Janssens, Salvatore Brugaletta, Christoph K Naber, Thomas Schmitz, Richard Anderson, Harald Rittger, Sergio Berti, Emanuele Barbato, Gabor G Toth, Luc Maillard, Christian M Valina, Paweł E Buszman, Holger Thiele, Volker Schächinger, William Wijns
BACKGROUND: In the prospective, multicentre, randomised TARGET All Comers study, percutaneous coronary intervention (PCI) with the FIREHAWK biodegradable-polymer sirolimus-eluting stent (BP-SES) was non-inferior to the durable-polymer everolimus-eluting stent (DP-EES) for the primary endpoint of target lesion failure (TLF) at 12 months. AIMS: We aimed to report the final study outcomes at 5 years. METHODS: Patients referred for PCI were randomised to receive either a BP-SES or DP-EES in a 1:1 ratio in 10 European countries...
October 20, 2023: EuroIntervention